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Abstract 
Adrenergic alpha 2A receptors (ADRA2A) are known to play an important role in 
descending pain pathways and in the generation of stress-induced analgesia. However, 
the influence of ADRA2A genetic variants on acute pain severity after motor vehicle 
collision (MVC) has not been assessed. In this study we hypothesized that a genetic 
variant in the 3’UTR of ADRA2A, rs3750625, would be associated with acute pain 
outcomes following MVC. In addition, based on bioinformatics analyses, we 
hypothesized that the allele at this location determines the efficiency of binding of miR-
34a, a microRNA (miRNA) known to regulate pain and stress responses. The association 
between rs3750625 allele and acute post-MVC pain outcomes was assessed using a study 
of 948 European Americans who presented to the emergency department (ED) for 
evaluation after MVC. The rs3750625 genotype was determined from patient blood ED 
samples using the Sequenom platform. miRNA binding was assessed using a luciferase 
reporter assay consisting of a miR-34a expression cassette and individual ADRA2A 
3’UTR-luc reporters with either the minor or major allele. In regression models adjusted 
for age, sex, and study site, the minor allele (A) of rs3750625 (n =91/942, 9.7%) was 
associated with greater ED pain severity (38.3 vs. 26.1), p=0.002). Luciferase reporter 
assays demonstrated that miR-34a binds the 3’UTR of ADRA2A and that the amount of 
knockdown is significantly more efficient when the minor allele is present. Additionally, 
knocking down miR-34a levels in neuroblastoma cells results in increased ADRA2A 
mRNA and protein expression. These results suggest that genetic variant rs3750625 in 
the 3’UTR of ADRA2A affects individual vulnerability to acute pain after traumatic 
events such as MVC, and that this influence may be mediated by miRNA binding. 
 
Introduction 
Small variants in the genome, such as single-nucleotide polymorphisms (SNPs), are 
sufficient to alter phenotypic outcomes.1 With increasingly more accurate technologies 
for genome sequencing, a number of polymorphisms have been found to be associated 
with pain.2, 3 However, it is often unclear what molecular mechanistic role these 
polymorphisms play in pain pathways.  
The alpha-2A adrenergic receptor (ADRA2A) is important in negative feedback 
inhibition of catecholamines in the peripheral nervous system, and has been found to be 
associated with disorders such as ADHD and schizophrenia. Adrenergic receptors have 
also been found to be mediators of both pain and stress outcomes. Donello et al. found 
that ADRA2A plays a role in the development of stress-induced pain in preclinical 
models by measuring pain tolerance after stress in wild type and ADRA2A knockout 
mice. They present a model suggesting that without ADRA2A to function as a regulator 
of neurotransmission after stress, catecholamines accumulate and can sensitize peripheral 
nerves, leading to hyperalgesia.4 Additionally, Taneja et al. found that ADRA2A is 
involved in recovery after unexpected stress exposure.5 Genetic variants that regulate 
ADRA2A expression are therefore likely to affect pain and stress outcomes.  
 MicroRNAs (miRNAs) are small, non-coding RNAs that affect protein expression 
by regulating the stability and translation of mRNA. Canonically, miRNAs inhibit 
translation by binding to mRNA targets at a 6-8-nucleotide long seed region. The 
endogenous levels of miRNAs in a person’s body can change drastically due to 
environmental stimuli, including stress. A number of miRNAs have been shown to be 
associated with pain development.6 One miRNA, miR-34a, has previously been shown to 
play a role in both stress and pain.7, 8   
 In our study, we hypothesized that genetic variants in ADRA2A affect pain 
development after motor vehicle collision, and that is mediated by a miR-34a interaction. 
My work focused most specifically on the effect of the rs3750625 polymorphism on the 
binding efficiency of miR-34a to ADRA2A, and how that binding impacts ADRA2A 
expression. 
 
 
Methods 
 
Initial Data Collection 
Patient blood sample collection, genotyping, and statistical analyses were completed as 
part of a previously described MVC study.9 The cohort in the MVC study consisted of 
European Americans aged 18-65 years, presenting to one of eight emergency departments 
(EDs) within 24 hours of motor vehicle collision, but requiring no hospital admission. 
Patients were excluded who could not read and understand English, who were pregnant 
or prisoners, who were taking a β-adrenoreceptor antagonist, or who were taking opioids 
above a total daily dose of 30 mg of oral morphine or equivalent. Characteristics of study 
participates can be found in Table 1. 
Blood samples were taken from study participants in the ED using PAXgene 
DNA tubes. Samples were purified with PAXgene blood DNA kit (QIAGEN) and 
genotyped using the Sequenom platform. Pain assessments and statistical analyses were 
completed by members of the UNC Anesthesiology Research Department. 
 
Bioinformatics Analyses 
The potential effect of rs3750625 on miRNA binding was found using bioinformatics 
analyses using the miRdSNP algorithm found at: 
http://mirdsnp.ccr.buffalo.edu/search.php.10 
 
Constructs 
For the dual-luciferase assays I used lentiviral constructs containing either FLUC (pL-
SV40-GL3) or RLUC (pL-SV40-RLUC) as previously described.11 The 3’UTR of 
ADRA2A was isolated from human genomic DNA using primers 1-F and 1-R 
(Supplementary Table 1). The resulting 1360bp insert was cloned into pL-SV40-GL3 
using XhoI and EcoRI restriction enzyme sites. This newly created construct, a2A-C, was 
sequenced to confirm the major allele, C, at position rs3750625 in the ADRA2A 3’UTR. 
With a2A-C as the parent construct, position rs3750625 was mutated from the major 
allele, C, to the minor allele, A, to create a second construct, a2A-A. Site-directed 
mutagenesis was completed using the QuickChange II Site-Directed Mutagenesis Kit 
(Promega) and primers designed to replace the major allele with the minor allele, A, at 
rs3750625 (Primers 2-F, 2-R, Supplementary Table 1). 
Two-step PCR was used to mutate the seed region and the compensatory site in 
the ADRA2A 3’UTR. Again, a2A-C was used as the parent construct, and primers with 
mismatched base pairs at either the seed region or compensatory site were used to create 
constructs a2A-C-seed (Primers 7-F, 7-R, Supplementary Table 1) and a2A-C-comp 
(Primers 6-F, 6-R, Supplementary Table 1), respectively. 
 
Cell culture and generation of viral transductants 
HEK 293 cells are neuroendocrine cells obtained by transformation of human embryonic 
kidney cells with sheared adenovirus 5 DNA. IMR-32 cells are human neuroblastoma 
cells. SH-SY5Y cells are cells derived from the subcloning of neuroblastoma cell line 
SK-N-SH. All cell lines were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
with 10% fetal bovine serum (FBS) and 1% gentamicin. 
To measure levels of ADRA2A mRNA and protein after miR-34a knockout, we 
used a third generation lentiviral packaging system as previously described.12 Briefly, 
HEK 293 cells were transfected with vectors pMD2-VSVG, pRSV-REV, pMDLgp, and 
either pLCE s34 (miR-34a sponge), pLCE (control), or PLCE CXCR4 (CXCR4 sponge, 
control) using Fugene 6 Transfection Reagent (Promega). 48 hours after transfection, 
viral media was collected, filtered using Amicon Ultra centrifugal columns, and 
concentrated by centrifugation. 
In preparation for transduction, IMR-32 and SH-SY5Y cells were plated and 
incubated until 70-90% confluency. On the day of transduction, growth media for both 
cell lines was replaced at half volume. Concentrated viral media was added to the 
supernatant covering the neuroblastoma cells. After 16 hours, media was replaced. After 
72 hours transducted cells were checked for GFP expression and sorted using 
fluorescence-activated cell sorting (FACS). 
 
qRT-PCR and Western blotting  
qRT-PCR was used to analyze ADRA2A mRNA levels in IMR-32 cells after miR-34a 
knock-down. Random primers were used for reverse transcription as described (High 
Capacity Reverse Transcription Kit, Life Technologies) and SYBR reagents were used 
for qPCR with transcript-specific primers (Life Technologies).  
Total protein was collected by lysing IMR-32 cells in RIPA buffer (Pierce, a 
subsidiary of Thermo Scientific, Rockford IL), protein concentration was measured with 
a BCA Protein Assay (Pierce), and analysis was completed by Western blotting. 
 
Dual luciferase assays 
miR-34a binding to ADRA2A was assessed using the previously described FLUC and 
RLUC-based indicator vectors, pL-SV40-GL3 and pL-SV40-RLUC.11 To show miR-34a 
functional binding to ADRA2A, HEK 293 cells were co-transfected with pcDNA miR-34a 
expression construct (pC-34a) and either a2A-C or pL-SV40-RLUC using Fugene 6 
Transfection Reagent (Promega). To show differences in binding efficiency between the 
major and minor allele at rs3750625, HEK 293 cells were co-transfected with pC-34a, 
pL-SV40-RLUC, either a2A-C or a2A-A, and a GFP reporter plasmid (pLCE). In both 
experiments, we transfected with 20fmol, 60fmol, and 150fmol of pC-34a in order to test 
the dose-dependency of binding. In order to ensure equal total volumes of DNA at 
transfection, we added variable amounts of pLCE depending on the amount of pC-34a. 
After 48 hours of incubation, transfected cells were collected and lysed. RLUC and 
FLUC levels were read using a dual luciferase reporter assay (Promega).  FLUC/RLUC 
ratios were calculated and normalized to ratios obtained from HEK 293 cells with a 
mutated miR-34a expression construct, pC-34a-mut. 
 
 
Results 
 
Association of ADRA2A polymorphisms with the severity of pain after MVC 
As stated previously in the MVC study, it was found that patients with the minor allele 
(A) at rs3750625 in the 3’UTR of ADRA2A experience significantly greater pain 
severity (body burden of pain) following MVC (p = 0.002, Table 2). The minor allele (A) 
at rs3750625, which occurs in 10% of the cohort, can then be referred to as the risk allele.  
 
rs3750625 is located in the seed binding region of miR-34a 
Given the significance of rs3750625 to pain outcomes, and its location in the 3’UTR of 
an adrenergic receptor, we wanted to see if this polymorphism had the potential to impact 
expression of ADRA2A. Using the miRdSNP algorithm,10 we found that rs3750625 is 
located in the seed binding region of miR-34a, where the risk allele creates a completely 
complementary site (Figure 1A).  
Genetic conservation among species is a good predictor of functional importance, 
and we found that rs3750625 is highly conserved among species (Figure 1B).  
 
miR-34a binds to the ADRA2A 3’UTR in a dose dependent fashion and the 
efficiency of miR-34a binding is dependent on whether the risk allele is present at 
rs3750625 
The presence of a miR-34a binding site in ADRA2A does not ensure that functional 
binding of miR-34a actually occurs. For this reason, I wanted to test functional binding of 
miR-34a to ADRA2A, first with the presence of the major allele (C) at rs3750625. Using a 
luciferase assay to visualize functional binding in HEK 293 cells, I found that miR-34a 
binds to the 3’UTR of ADRA2A in a dose dependent fashion (Figure 1C).  
With the presence of the major allele (C) at rs3750625, there is an imperfect seed 
binding site for miR-34a (Figure 1A), yet we still see dose-dependent binding (Figure 
1C). The presence of the minor allele (A), however, makes a fully complementary miR-
34a seed binding region, suggesting that this polymorphism could significantly impact 
binding. Using a luciferase assay and constructs with either the major allele (C) or risk 
allele (A), I tested the difference in miR-34a binding efficiency with either variant at 
rs3750625. With both the major allele and risk allele we see dose-dependent binding of 
miR-34a to the 3’UTR of ADRA2A, showing that binding can functionally occur with 
either allele present. More importantly, with each amount of miR-34a (20fmol, 60fmol, 
and 150fmol), I saw consistently more binding with the risk allele (A) than with the 
major allele (C) at rs3750625. This shows that the presence of the risk allele at rs3750625 
increased binding efficiency of miR-34a to the 3’UTR of ADRA2A. 
 
The seed region of the miR-34a binding site confers the majority of miR-34a 
specificity for ADRA2A 
While the seed region of a miRNA is the most important region for binding, the 
compensatory regions have also been shown to contribute to the gene silencing effects of 
miRNAs.13 miR-34a has a compensatory region just upstream of its seed binding site 
(Figure 2A). To see whether the compensatory site in miR-34a significantly contributes 
to its ability to bind to the 3’UTR of ADRA2A, I tested miR-34a binding using vectors 
with either seed region or compensatory region mutations. With a mutated seed region, 
we see luciferase knockdown comparable to the control, meaning miR-34a binding was 
effectively disrupted by the mutation. This is contrary to what we see with a mutated 
compensatory site, where the amount of binding is equivalent to when there are no 
mutations (Figure 2B). We can conclude, then, that the compensatory region in miR-34a 
does not significantly contribute to miR-34a binding to ADRA2A, and that the majority of 
binding specificity comes from the seed region where our polymorphism of interest is 
located. 
 
Knockdown of miR-34a in an adrenergic neuroblastoma cell line affects ADRA2A 
mRNA and protein levels 
Knowing that miR-34a can functionally bind to ADRA2A, I next wanted to see whether 
this miRNA functions as a gene silencer and down-regulates ADRA2A expression. In 
order to test the effect of miR-34a on ADRA2A expression, I knocked down miR-34a in 
a neuroblastoma cell line, IMR-32, and looked at both mRNA and protein levels. IMR-32 
cells express miR-34a and ADRA2A (data not shown) and exhibit adrenergic 
neurotransmitter properties, making them an ideal cell line to work in.14 miR-34a knock-
down was completed using a miR-34a-specific sponge (s34), and an unrelated sponge 
(sCXCR4) was used as a control. Using qPCR to measure mRNA levels, I saw a 
significant increase in ADRA2A mRNA levels when miR-34a was knocked down (Figure 
3A). In a similar fashion, with the use of a Western blot I saw a significant increase in 
ADRA2A protein levels when s34 was transfected into IMR-32 cells (Figure 3B). These 
results show that miR-34a has significant effects on the transcription and translation of 
ADRA2A in co-expressing cells.  
 
Discussion 
 
In this research, we found that ADRA2A expression can be regulated by miR-34a and 
that the interaction may explain the correlation between a genetic variation and 
differences in pain severity after MVC. We identified a specific genetic polymorphism, 
rs3750625, which predicts pain severity after a stressful event. This may have clinical 
implications. New knowledge of polymorphisms and their roles in pain and stress 
pathways may change the way that individuals are treated in the emergency department 
after stress exposure. More broadly, a clearer understanding of how genetic variations 
change physiological outcomes can lead the way for the development of more 
personalized medicine.  
We also identified a novel miRNA event and showed how it is connected to a 
clinical outcome. This has implications for the treatment of not only pain, but also a 
number of other diseases. If the role of miRNAs in disease pathologies can be elucidated, 
there is potential for new therapies that target specific miRNAs or miRNA populations.  
Finally, this research gives us a fuller understanding of ADRA2A, it’s role in the 
mediation of post-stress pain, and the ways in which it is regulated. Since we know that 
adrenergic receptors play a vital role in many cellular pathways, our findings could help 
further elucidate the broader functions of these receptors in disease outcomes. 
 
Troubleshooting 
 
One aspect of this project that was particularly tough was the creation of a vector with the 
risk allele (A) at rs3750625. Vector a2A-C contained the major allele (C) at this location, 
so a point mutation, from (C) to (A), was necessary in order to create a new plasmid with 
the risk allele at rs3750625. In order to complete this mutation, I used the QuikChange II 
XL Site-Directed Mutagenesis kit (Agilent Technologies). Initial attempts to mutate a2A-
C were unsuccessful due to failed PCR, and I found that tweaking the primer design and 
the given PCR protocol were necessary to create the final product. 
 
Primer design 
The QuikChange method uses PCR and user-designed primers containing the 
allelic change, to mutate a parent plasmid (in my case, a2A-C) into the desired 
plasmid. Since the primers contain the mutant, they are not completely 
complementary, however ideally this is not an issue because there are enough 
complementary nucleotides flanking the mismatch to induce binding. Initially, my 
initially primers were 32 nucleotides long with a melting temperature of 72.2°C, 
which is quite high for a melting temperature. The primers used during successful 
PCR were 25 nucleotides long with a 67°C melting temperature. From this, I 
learned that a 25-base pair primer contains enough complementary nucleotides to 
bind to the parent plasmid with one mismatch, and is preferable to a longer primer 
with a melting temperature above 70°C.  
 
Protocol 
Since initial PCR attempts were unsuccessful, even with new, shorter primers, I 
tweaked the given protocol in a few areas and found success.   
The QuikChange protocol suggests using 125ng of each primer, a melting 
temperature of 60°C, and does not include DMSO in its PCR mix.  
I found success using 140ng of each primer, an increased melting temperature of 
68°C to match my primers, and 3% DMSO. DMSO is often used to enhance PCR 
outcomes, as it facilitates annealing by helping to break apart nucleic acid strands. 
Due to the high variability in uses of the QuikChange method, it is not surprising 
that a uniform protocol may not work for all users. Others experiencing issues 
using this kit may benefit from tweaking their primers design and melting 
temperature, as well as changing the primer volume, and including DMSO in their 
PCR mix.  
 
 
 Model 
 
This research supports the model of post-stress hyperalgesia put forth by Donello et al. 
Their work showed how knocking out ADRA2A in mice increases hyperalgesia after 
stress. The model presented by Donello et al. suggests that a decrease in ADRA2A 
receptors, and thus less feedback inhibition of catecholamines, leads to catecholamine 
buildup and subsequent sensitization of the sensory afferents. This sensitization makes 
ADRA2A knockout mice more susceptible pain after exposure to stress.4 Our work 
suggests that this model may be true in humans as well.  
 
Future Direction 
 
Other members of my research group have begun to look at miR-34a and ADRA2A 
expression in rat tissues, specifically adrenal gland, peripheral nerve, dorsal root ganglia, 
and superior cervical ganglion tissues. These tissues were chosen because of the function 
of ADRA2A in neurotransmission and regulation of catecholamine release. In order for 
miR-34a to interact with ADRA2A mRNA in-vivo, both must be present in the same 
tissues. Overlapping expression of miR-34a and ADRA2A was found in each of the 
aforementioned tissues. This further suggests that miR-34a plays a vital role in the 
nervous system as a regulator of ADRA2A expression. 
Additionally, preliminary data has shown that stressed rats have dysregulated 
miR-34a and ADRA2A levels. Knowing this, it would be interesting to look more closely 
at the connection between miR-34a, ADRA2A, and catecholamine feedback. The model 
put forth by Donello et al. suggests that the dysregulation of ADRA2A disrupts normal 
catecholamine feedback in peripheral nerves, leading to sensitization and then 
hyperalgesia. It would be worthwhile to translate this animal model to a human model. If 
it is supported by further studies, this model may be a convincing explanation for the 
increased pain we see in patients with the minor allele, (A) at rs3750625. Future studies 
might measure circulating catecholamine levels in patients after MVC to evaluate 
significant differences in those with the (A) or (C) allele.  
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 Table 1. Baseline characteristics of study participants   
Characteristic  
Enrolled, n 948 
Age, years, mean (SD) 36 (13) 
Females, n(%) 575 (61) 
Education, n(%)  
8-11 yrs 42 (4) 
HS 184 (19) 
Post-HS 57 (6) 
Some college 311 (33) 
College 237 (25) 
Post-college 113 (12) 
Overall pain, 0-10 NRS, mean(SD)  
Past month 0.4 (0.5) 
ED 5.5 (2.4) 
rs3750625, n(%)  
    CC 854 (90) 
    CA or AA 91 (10) 
 
 
 	  	  
	  	  	  	  	  	  	  	  	  	  	  
Table 2. Association of the ADRA2A genotype with pain severity in the ED following motor vehicle 
collision  (n = 878) 
 
  Pain Severity (Body burden of pain)  
SNP Alleles C/C    C/A + A/A p-value  
rs3750625 C/A 26.1 38.8 0.002  
*adjusted for age, sex, study site, education, and BMI.  
	  
Figure 1: Specifications of miR-34a binding to ADRA2A and experimental assessment of 
functional binding.  
[A] rs3750625 (black arrow, bolded nucleotides) is found within a predicted seed binding site of 
miR-34a (underlined nucleotides). Binding between miR-34a and ADRA2A with either the (C) 
allele or the (A) allele is shown with vertical black lines. A mismatch exists at rs3750625 when 
the (C) allele is present.  
[B] The genetic variant rs3750625 (indicated by the bolded arrow) is highly conserved among 
seven mammals.  
[C] Relative luciferase activity (y-axis) is shown after co-transfection of miR-34a and a2A-C in 
HEK 293T cells. miR-34a binding (black bars) is compared to binding of a control miRNA (open 
bars). The assay was completed in triplicated and error bars show standard error of the mean.  
[D] Relative luciferase activity (y-axis) is shown after transfection with miR-34a and either a2A-
C (grey line, grey squares) or a2A-A (black line, black circles) in HEK 293T cells. The assay was 
completed in triplicated and error bars show standard error of the mean. 	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Figure 2: Specificity of miR-34a binding shown using mutation of compensatory and seed 
regions.  
[A] Relative location of seed and compensatory binding regions of miR-34a in 1.4kb ADRA2A 
3’UTR. Grey boxes and bolded nucleotides represent experimental mutations made to test 
binding specificity.  
[B] Relative luciferase activity (y-axis) after transfection with miR-34a and ADRA2A 3’UTR with 
no mutations (WT), with mutations in the seed region (seed mut) or with mutations in the 
compensatory region (comp mut). miR-34a binding (black bars) is compared to binding of a 
control miRNA (open bars). Experiment was completed in triplicate and error bars show standard 
deviation.  	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3’ UUGGUCGAUUC - - - - UGUGACGGU-5’    hsa-miR-34a 
 
Mutations in the compensatory binding region 
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3’ UUGGUCGAUUC - - - - UGUGACGGU-5’    hsa-miR-34a 
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Figure 3: Effect of miR-34a knockdown on ADRA2A mRNA and protein levels in 
neuroblastoma cells. miR-34a knockdown was completed using a miR-34a sponge, pLCE-s34. 
[A] Relative ADRA2A mRNA levels (y-axis) in IMR-32 cells expressing pLCE-s34 were 
measured using RT-qPCR. mRNA expression in cells expressing pLCE-s34 was compared to 
cells expressing an empty vector (pLCE) and a control miRNA sponge (sCXCR4). Error bars 
show standard deviation. 
[B] ADRA2A protein levels were measured in IMR-32 cells expressing pLCE-s34 using Western 
Blotting. Quantification of band intensity was calculated using band intensity measurements from 
the NIK image analysis program. 
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Supplementary Table 1	  	  
Primer 
Name Primer Sequence (5’ à  3’) Use 
Added 
R.E. site Species 
1-F ATGATGCTCGAGACTCAGAAACCCGGGCGC To make a2A-C XhoI human 
1-R ATGATGAATTCCCATAAAATCAGATGTTCCCAGAG To make a2A-C EcoRI human 
2-F GCTAAGGGCAGCACTGCCTGCCCTC For mutating rs3750625 to make a2A-A - human 
2-R GAGGGCAGGCAGTGCTGCCCTTAGC For mutating rs3750625 to make a2A-A - human 
3-F AGAAGTGGTACGTCATCTCGT qPCR Detection of ADRA2A mRNA   - human 
3-R CGCTTGGCGATCTGGTAGA qPCR Detection of ADRA2A mRNA   - human 
5-F TACTACACCGGTATGTTCCGCCAGGAGCAGCCG 
ADRA2A over-expression 
construct AgeI human 
5-R TACTACCTCGAGTCACACGATCCGCTTCCTGTCC 
ADRA2A over-expression 
construct XhoI human 
6-F AAAATGGTACCGGCAGCCCTGCCTGCCCTCC pL-GL3-ADRA2A-comp KpnI human 
6-R GCTGCCGGTACCATTTTTCTTTAAAAAGAGA pL-GL3-ADRA2A-comp KpnI human 
7-F GGCAGCCCGGGCTGCCCTCCCCATCCCCCGCT pL-GL3-ADRA2A-seed SmaI human 
7-R GGGCAGCCCGGGCTGCCCTTAGCATTTTTCTT pL-GL3-ADRA2A-seed SmaI human 	  	  
